Although the genetic backgrounds of prostate cancer cell lines are different, LBH589 treatment induces ERK activation and HDAC6 down-regulation in 22Rv1 and DU 145 PCa cell lines other than LNCaP cells (Figure S4). The gene discussed is HDAC6; the disease is prostate carcinoma.